The primary objective of this proposed research is to provide practical models and methods for the design, conduct, and analysis of complex clinical trials not accommodated by conventional trial designs. These are trials of experimental treatment regimens for which little is known about the effects of dose, dose-schedule combination, or dose sequence in multiple cycles, or about short-term or long-term adverse events (toxicities) or efficacy. All models and methods are Bayesian, which facilitates adaptive decision making and accounts for multiple sources of variability. A major difficulty is the inheren tension between the physician's desire to treat the patients enrolled in a trial ethically and the scientific goal to obtain information useful for treatment regime evaluation and refinement to benefit future patients. Consequently, to ensure ethical trials, the designs include sequential, outcome-adaptive "learn-as-you go" decision rules. In the settings considered here, this is complicated by the complexity of patient outcomes, which include both efficacy and toxicity variables, each possibly binary, ordinal, or continuous with possible interval censoring, in some cases observed over multiple treatment cycles. For most of the designs and methods, the desirability of each combination of possible outcomes is quantified by elicited numerical utilities which are used as the basis for adaptive decision-making. This formalizes the idea, inherent in virtually all medical decision-making, of trade-offs between desirable and undesirable therapeutic outcomes, and it provides a method for reducing multiple outcomes to a single decision criterion, the posterior mean utility of each treatment regime, quantifying the relative importance of the outcomes. Methods will be developed for eliciting numerical utilities and establishing utility functions, in the cases of bivariate or trivariate discrete outcomes, and for bivariate event times.
Specific Aim 3 is more general in that it accommodates any optimality criterion, including posterior mean utility, efficacy-toxicity probability trade-off, or the continal reassessment method criterion. In some trials with adaptive treatment assignment, the "exploration versus exploitation" problem may occur, wherein a greedy" algorithm that always chooses the empirically optimal regime may get stuck at a regime that actually is inferior. To deal with this, we will explore hybrid algorithms that include adaptive randomization to reduce the risk of choosing inferior regimes. Computer simulation will be used as a design tool to calibrate design parameters and prior parameters to obtain designs with good frequentist operating characteristics.
The Specific Aims are to develop (1) a phase I-II design to optimize (schedule, dose) regimes based on the joint utility of the times to response and toxicity, (2) a family of phase I-II designs, based on bivariate binary or bivariate ordinal (toxicity, efficacy), o optimize the dose sequence of an experimental agent given sequentially in multiple cycles, (3) an algorithm to improve the logistics of outcome-adaptive clinical trials by future data weighted randomization, and (4) phase I-II design, based on three outcomes, to optimize the sedation dose for preterm infants being intubated to treat respiratory distress syndrome. Efficient, user-friendly, freely available computer programs will be developed to facilitate widespread application.
The proposed research will provide designs for complex clinical trials that are more efficient, more scientifically valid, and more ethical than conventioal designs by (1) using more patient outcome data actually available during the trial to make real-time adaptive decisions, (2) incorporating elicited prior information, (3) basing adaptive decisions on utilities of patient clinical outcomes, (4) when appropriate, evaluating schedule-dose combinations or multi-cycle regimes rather than single treatments, and (5) combining separate phases of conventional treatment evaluation. The proposed methods will increase the chance of favorable therapeutic outcomes for patients in the trial, and benefit future patients by accelerating and improving treatment regime development, increasing the chances of identifying regimes providing substantive therapeutic improvements, and dropping unpromising or unsafe regimes.
|Thall, Peter F; Nguyen, Hoang Q; Zohar, Sarah et al. (2014) Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. J Am Stat Assoc 109:931-943|
|Tang, Xiaowen; Alatrash, Gheath; Ning, Jing et al. (2014) Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant 20:1139-44|
|Jin, Ick Hoon; Liu, Suyu; Thall, Peter F et al. (2014) Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. J Am Stat Assoc 109:525-536|
|Thall, Peter F; Herrick, Richard C; Nguyen, Hoang Q et al. (2014) Effective sample size for computing prior hyperparameters in Bayesian phase I-II dose-finding. Clin Trials 11:657-66|
|Wang, Lu; Shen, Jincheng; Thall, Peter F (2014) A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity Constraint. Stat Probab Lett 93:126-133|
|Wahed, Abdus S; Thall, Peter F (2013) Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia. J R Stat Soc Ser C Appl Stat 62:67-83|
|Thall, Peter F; Nguyen, Hoang Q; Braun, Thomas M et al. (2013) Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes. Biometrics 69:673-82|
|Thall, Peter F; Nguyen, Hoang Q; Wang, Xuemei et al. (2012) A Hybrid Geometric Phase II/III Clinical Trial Design based on Treatment Failure Time and Toxicity. J Stat Plan Inference 142:944-955|
|Thall, Peter F; Liu, Diane D; Berrak, Su G et al. (2011) Defining and ranking effects of individual agents based on survival times of cancer patients treated with combination chemotherapies. Stat Med 30:1777-94|
|Mathew, Paul; Wen, Sijin; Morita, Satoshi et al. (2011) Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. J Interferon Cytokine Res 31:539-44|
Showing the most recent 10 out of 41 publications